Nucleolar and spindle‑associated protein 1 promotes non‑small cell lung cancer progression and serves as an effector of myocyte enhancer factor 2D

Ling,Bo; Wei,Pengya; Xiao,Juan; Cen,Bingkui; Wei,Hong; Feng,Xueping; Ye,Guangbin; Li,Songbo; Zhang,Zhongwei; Liang,Wei; Huang,Suoyi; Huang,Wei

doi:10.3892/or.2020.7918

Nucleolar and spindle‑associated protein 1 promotes non‑small cell lung cancer progression and serves as an effector of myocyte enhancer factor 2D

Authors:
- Bo Ling
- Pengya Wei
- Juan Xiao
- Bingkui Cen
- Hong Wei
- Xueping Feng
- Guangbin Ye
- Songbo Li
- Zhongwei Zhang
- Wei Liang
- Suoyi Huang
- Wei Huang
View Affiliations

Affiliations: College of Pharmacy, Youjiang Medical University for Nationalities, Baise, Guangxi 533000, P.R. China, Laboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, P.R. China, Department of Thoracic Surgery, Chongqing General Hospital, Chongqing 400013, P.R. China
Published online on: December 30, 2020 https://doi.org/10.3892/or.2020.7918
Pages: 1044-1058
Copyright: © Ling et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As a potential oncogene, nucleolar and spindle‑associated protein 1 (NUSAP1) is involved in the regulation of tumor cell proliferation, metastasis and drug resistance. However, the role of NUSAP1 in non‑small cell lung cancer (NSCLC) remains unclear. The present study aimed to investigate the biological function and underlying molecular mechanisms of NUSAP1 in NSCLC. NUSAP1 expression was measured in NSCLC tissues and cell lines via immunohistochemistry and western blotting, respectively. NSCLC cell lines stably inhibiting NUSAP1 were established to investigate its effects on cell proliferation, colony formation and invasion, and on in vivo tumorigenicity. Additionally, the upstream and downstream mechanisms of NUSAP1 in regulating NSCLC progression were investigated. The results indicated that NUSAP1 expression was upregulated in NSCLC tissues and cell lines. High NUSAP1 expression was associated with tumor size, TNM stage, lymph node metastasis and poor patient survival, whereas knockdown of NUSAP1 inhibited NSCLC cell proliferation, colony formation and invasion. Furthermore, downregulation of NUSAP1 decreased the growth of NSCLC xenografts in vivo. In addition, myocyte enhancer factor 2D (MEF2D) directly targeted the NUSAP1 promoter, thereby enhancing the mRNA and protein expression levels of NUSAP1. Moreover, the results demonstrated that MEF2D expression was upregulated in NSCLC tissues and was positively correlated with NUSAP1 expression. MEF2D‑knockdown decreased NSCLC cell proliferation, colony formation and invasion. NUSAP1 upregulation reversed the effects of MEF2D‑knockdown on NSCLC progression. Furthermore, it was observed that MEF2D‑knockdown inhibited the accumulation and nuclear translocation of β‑catenin, thereby repressing the activation of the Wnt/β‑catenin signaling pathway in NSCLC cells, whereas NUSAP1 upregulation rescued the effects of MEF2D‑knockdown on the activation of the Wnt/β‑catenin signaling pathway. In conclusion, the findings of the present study indicated that the MEF2D/NUSAP1 signaling pathway promoted NSCLC progression by inducing the activation of Wnt/β‑catenin signaling, and this novel mechanism may represent a potential treatment target for patients with NSCLC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 67:7–30. 2018. View Article : Google Scholar
2	Domvri K, Zarogoulidis P, Darwiche K, Browning RF, Li Q, Turner JF, Kioumis I, Spyratos D, Porpodis K, Papaiwannou A, et al: Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy. J Cancer. 4:736–754. 2013. View Article : Google Scholar : PubMed/NCBI
3	Kim KW, Myers CJ, Jung DK and Lu B: NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/mTOR pathway in cisplatin-resistant non-small cell lung carcinoma. Genes Cancer. 5:293–302. 2014. View Article : Google Scholar : PubMed/NCBI
4	Hussain S, Benavente SB, Nascimento E, Dragoni I, Kurowski A, Gillich A, Humphreys P and Frye M: The nucleolar RNA methyltransferase Misu (NSun2) is required for mitotic spindle stability. J Cell Biol. 186:27–40. 2009. View Article : Google Scholar : PubMed/NCBI
5	Li C, Zhang Y, Yang Q, Ye F, Sun SY, Chen ES and Liou YC: NuSAP modulates the dynamics of kinetochore microtubules by attenuating MCAK depolymerisation activity. Sci Rep. 6:187732016. View Article : Google Scholar : PubMed/NCBI
6	Ribbeck K, Groen AC, Santarella R, Bohnsack MT, Raemaekers T, Köcher T, Gentzel M, Görlich D, Wilm M, Carmeliet G, et al: NuSAP, a mitotic RanGTP target that stabilizes and cross-links microtubules. Mol Biol Cell. 17:2646–2660. 2006. View Article : Google Scholar : PubMed/NCBI
7	Kokkinakis DM, Liu X and Neuner RD: Modulation of cell cycle and gene expression in pancreatic tumor cell lines by methionine deprivation (methionine stress): Implications to the therapy of pancreatic adenocarcinoma. Mol Cancer Ther. 4:1338–1348. 2005. View Article : Google Scholar : PubMed/NCBI
8	Ryu B, Kim DS, DeLuca AM and Alani RM: Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS One. 2:e5942007. View Article : Google Scholar : PubMed/NCBI
9	Gordon CA, Gong X, Ganesh D and Brooks JD: NUSAP1 promotes invasion and metastasis of prostate cancer. Oncotarget. 8:29935–29950. 2017. View Article : Google Scholar : PubMed/NCBI
10	Chen DT, Nasir A, Culhane A, Venkataramu C, Fulp W, Rubio R, Wang T, Agrawal D, McCarthy SM, Gruidl M, et al: Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue. Breast Cancer Res Treat. 119:335–346. 2010. View Article : Google Scholar : PubMed/NCBI
11	Liu R, Guo CX and Zhou HH: Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen. Cancer Biol Ther. 16:317–324. 2015. View Article : Google Scholar : PubMed/NCBI
12	Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D, Speights VO, Stankiewicz E, Foster CS, et al: Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study. Lancet Oncol. 12:245–255. 2011. View Article : Google Scholar : PubMed/NCBI
13	Li H, Zhang W, Yan M, Qiu J, Chen J, Sun X, Chen X, Song L and Zhang Y: Nucleolar and spindle associated protein 1 promotes metastasis of cervical carcinoma cells by activating Wnt/β-catenin signaling. J Exp Clin Cancer Res. 38:332019. View Article : Google Scholar : PubMed/NCBI
14	Roy S, Hooiveld GJ, Seehawer M, Caruso S, Heinzmann F, Schneider AT, Frank AK, Cardenas DV, Sonntag R, Luedde M, et al: microRNA 193a-5p regulates levels of Nucleolar- and spindle-associated Protein 1 to suppress hepatocarcinogenesis. Gastroenterology. 155:1951–1966. 2018. View Article : Google Scholar : PubMed/NCBI
15	Bidkhori G, Narimani Z, Hosseini Ashtiani S, Moeini A, Nowzari-Dalini A and Masoudi-Nejad A: Reconstruction of an integrated genome-scale co-expression network reveals key modules involved in lung adenocarcinoma. PLoS One. 8:e675522013. View Article : Google Scholar : PubMed/NCBI
16	Xu Z, Wang Y, Xiong J, Cui F, Wang L and Peng H: NUSAP1 knockdown inhibits cell growth and metastasis of non-small-cell lung cancer through regulating BTG2/PI3K/Akt signaling. J Cell Physiol. 235:3886–3893. 2020. View Article : Google Scholar : PubMed/NCBI
17	Kay FU, Kandathil A, Batra K, Saboo SS, Abbara S and Rajiah P: Revisions to the tumor, node, metastasis staging of lung cancer (8th edition): Rationale, radiologic findings and clinical implications. World J Radiol. 9:269–279. 2017. View Article : Google Scholar : PubMed/NCBI
18	Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L, Rodrigues M, Alves VA, Schmitt F and Baltazar F: Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch. 452:139–146. 2008. View Article : Google Scholar : PubMed/NCBI
19	Lin JX, Xie XS, Weng XF, Qiu SL, Xie JW, Wang JB, Lu J, Chen QY, Cao LL, Lin M, et al: Overexpression of IC53d promotes the proliferation of gastric cancer cells by activating the AKT/GSK3β/cyclin D1 signaling pathway. Oncol Rep. 41:2739–2752. 2019.PubMed/NCBI
20	Wang CJ, Zhou ZG, Holmqvist A, Zhang H, Li Y, Adell G and Sun XF: Survivin expression quantified by Image Pro-Plus compared with visual assessment. Appl Immunohistochem Mol Morphol. 17:530–535. 2009. View Article : Google Scholar : PubMed/NCBI
21	Knutsen A, Adell G and Sun XF: Survivin expression is an independent prognostic factor in rectal cancer patients with and without preoperative radiotherapy. Int J Radiat Oncol Biol Phys. 60:149–155. 2004. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory animals, . Guide for the Care and Use of Laboratory Animals. 8th edition. National Academies Press; Washington, DC: 2011, https://www.ncbi.nlm.nih.gov/books/NBK54050/
24	Rhodes DR, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, Kalyana-Sundaram S, Lonigro RJ, Helgeson BE, Bhojani MS, et al: AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci USA. 106:10284–10289. 2009. View Article : Google Scholar : PubMed/NCBI
25	Stewart DJ: Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst. 106:djt3562014. View Article : Google Scholar : PubMed/NCBI
26	Xu K and Zhao YC: MEF2D/Wnt/β-catenin pathway regulates the proliferation of gastric cancer cells and is regulated by microRNA-19. Tumour Biol. 37:9059–9069. 2016. View Article : Google Scholar : PubMed/NCBI
27	I H and Cho JY: Lung cancer biomarkers. Adv Clin Chem. 72:107–170. 2015. View Article : Google Scholar : PubMed/NCBI
28	Han G, Wei Z, Cui H, Zhang W, Wei X, Lu Z and Bai X: NUSAP1 gene silencing inhibits cell proliferation, migration and invasion through inhibiting DNMT1 gene expression in human colorectal cancer. Exp Cell Res. 367:216–221. 2018. View Article : Google Scholar : PubMed/NCBI
29	Wu X, Xu B, Yang C, Wang W, Zhong D, Zhao Z, He L, Hu Y, Jiang L, Li J, et al: Nucleolar and spindle associated protein 1 promotes the aggressiveness of astrocytoma by activating the Hedgehog signaling pathway. J Exp Clin Cancer Res. 36:1272017. View Article : Google Scholar : PubMed/NCBI
30	Gulzar ZG, McKenney JK and Brooks JD: Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1. Oncogene. 32:70–77. 2013. View Article : Google Scholar : PubMed/NCBI
31	Reichert N, Wurster S, Ulrich T, Schmitt K, Hauser S, Probst L, Götz R, Ceteci F, Moll R, Rapp U and Gaubatz S: Lin9, a subunit of the mammalian DREAM complex, is essential for embryonic development, for survival of adult mice, and for tumor suppression. Mol Cell Biol. 30:2896–2908. 2010. View Article : Google Scholar : PubMed/NCBI
32	Ma L, Liu J, Liu L, Duan G, Wang Q, Xu Y, Xia F, Shan J, Shen J, Yang Z, et al: Overexpression of the transcription factor MEF2D in hepatocellular carcinoma sustains malignant character by suppressing G2-M transition genes. Cancer Res. 74:1452–1462. 2014. View Article : Google Scholar : PubMed/NCBI
33	Zhu HX, Shi L, Zhang Y, Zhu YC, Bai CX, Wang XD and Zhou JB: Myocyte enhancer factor 2D provides a cross-talk between chronic inflammation and lung cancer. J Transl Med. 15:652017. View Article : Google Scholar : PubMed/NCBI
34	Zhang R, Zhang Y and Li H: miR-1244/myocyte enhancer factor 2D regulatory loop contributes to the growth of lung carcinoma. DNA Cell Biol. 34:692–700. 2015. View Article : Google Scholar : PubMed/NCBI
35	Su L, Luo Y, Yang Z, Yang J, Yao C, Cheng F, Shan J, Chen J, Li F, Liu L, et al: MEF2D transduces microenvironment stimuli to ZEB1 to promote epithelial-mesenchymal transition and metastasis in colorectal cancer. Cancer Res. 76:5054–5067. 2016. View Article : Google Scholar : PubMed/NCBI
36	Chen L, Wei T, Si X, Wang Q, Li Y, Leng Y, Deng A, Chen J, Wang G, Zhu S and Kang J: Lysine acetyltransferase GCN5 potentiates the growth of non-small cell lung cancer via promotion of E2F1, Cyclin D1, and Cyclin E1 expression. J Biol Chem. 288:14510–14521. 2013. View Article : Google Scholar : PubMed/NCBI
37	Li K, Pan J, Wang J, Liu F and Wang L: MiR-665 regulates VSMCs proliferation via targeting FGF9 and MEF2D and modulating activities of Wnt/β-catenin signaling. Am J Transl Res. 9:4402–4414. 2017.PubMed/NCBI
38	Shang S, Hua F and Hu ZW: The regulation of β-catenin activity and function in cancer: Therapeutic opportunities. Oncotarget. 8:33972–33989. 2017. View Article : Google Scholar : PubMed/NCBI
39	Zhou P, Jiang W, Zhang YJ, Kahn SM, Schieren I, Santella RM and Weinstein IB: Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene. 11:571–580. 1995.PubMed/NCBI
40	Jiang Q, He M, Ma MT, Wu HZ, Yu ZJ, Guan S, Jiang LY, Wang Y, Zheng DD, Jin F and Wei MJ: MicroRNA-148a inhibits breast cancer migration and invasion by directly targeting WNT-1. Oncol Rep. 35:1425–1432. 2016. View Article : Google Scholar : PubMed/NCBI
41	Yue X, Zhao Y, Xu Y, Zheng M, Feng Z and Hu W: Mutant p53 in cancer: Accumulation, gain-of-function, and therapy. J Mol Biol. 429:1595–1606. 2017. View Article : Google Scholar : PubMed/NCBI
42	Sankala H, Vaughan C, Wang J, Deb S and Graves PR: Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance. Arch Biochem Biophys. 512:52–60. 2011. View Article : Google Scholar : PubMed/NCBI
43	Muller PA, Trinidad AG, Timpson P, Morton JP, Zanivan S, van den Berghe PV, Nixon C, Karim SA, Caswell PT, Noll JE, et al: Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene. 32:1252–1265. 2013. View Article : Google Scholar : PubMed/NCBI
44	Buganim Y, Kalo E, Brosh R, Besserglick H, Nachmany I, Rais Y, Stambolsky P, Tang X, Milyavsky M, Shats I, et al: Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction. Cancer Res. 66:10750–10759. 2006. View Article : Google Scholar : PubMed/NCBI